Alnylam’s HELIOS-B Review: Conflicting Insights Analyzed
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
- Latest
- Trending
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
Zealand Pharma's stock surged 17% post-positive trial results for its weight loss drug, showing promising 8.6% average weight reduction. Analysts ...
Jazz Pharmaceuticals hits a hurdle as its essential tremor drug trial misses primary endpoint. Awaiting Parkinson's trial results for future ...
Esperion's stock downgraded by BofA due to rising competition from Merck's PCSK9 inhibitors. Analysts weigh in on efficacy and market ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
The stock has dropped 29% in the last year, hitting a low of $11.25 on Oct. 27. A study shows ...
Otsuka's phase 3 trial for AVP-786 in treating agitation in Alzheimer's patients has failed to meet the primary efficacy endpoint. ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.